PAST AND PRESENT TRENDS OF DRY POWDER INHALER DEVICES: A REVIEW by REDDY, SHARATH
Reddy et al                                           Journal of Drug Delivery & Therapeutics; 2014, 4(1), 97-107   97 
© 2011, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                                    CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
REVIEW ARTICLE 
PAST AND PRESENT TRENDS OF DRY POWDER INHALER DEVICES: A REVIEW 
*Sharath Chandra Reddy, Kapileshwar Swain, H.G.Shivakumar, VNSK Varma, Mahesh G. 
Department of Pharmaceutics, JSS College of pharmacy, JSS University, S. S. Nagar, Mysore, India-570015 
 
*Corresponding Author’s E-mail: sharathreddy341@gmail.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION: 
The key rationale for the introduction of  DPIs is the 
irremediable damage that is caused to the ozone layer by 
the chlorofluorocarbon propellants (CFC) 1 that are 
frequently used in pressurised metered dose inhalers 
(pMDIs) for the well gain the Pharmaceutical industry 
consequently made a firm decision to the development of 
nonchlorofluorocarbons (CFC) propellants for use in 
pMDIs and also DPIs which do not make use of any 
propellant, though the provoked thought of making the 
reformulation by the change of  propellant that is used in 
pMDIs that are based on hydrofluoroalkanes  replacing 
CFC there are some problems as it is not so simple to 
substitute with each other producing a similar properties. 
The first such DPIs were similar to the SpinhalerTM, for 
example salbutamol2 and beclometasone dipropionate3 
delivered via the RotahalerTM (GlaxoSmithKline) and 
Ipratropium bromide delivered by the AerohalerTM 
(Boehringer- Ingelheim)4. Dose emission from some of 
these DPIs was less than that from that of pMDI and 
therefore the recommended doses from the DPIs were 
double those from a pMDI. Gradually, a next generation 
of novel DPIs became available with extensively 
different designs, operating characteristics and improved 
drug delivery to the lung. Some devices contained a 
reservoir of drug such as the TurbuhalerTM (Astra 
Zeneca), ClickhalerTM (Innovata Biomed), and 
EasyhalerTM (Orion), while other devices had 
individually sealed unit doses of drug, such as the 
DiskhalerTM (GlaxoSmithKline) and DiskusTM 
(GlaxoSmithKline). Some DPIs, such as the Clickhaler
TM
 
and EasyhalerTM were designed to resemble pMDIs as 
closely as possible while other devices, such as 
DiskusTM, were designed to facilitate easy use and 
patient acceptability. 
Considerations of an ideal device: 
1. A device which is simple to use, carry, contains 
multiple doses, protects the drug from moisture and 
has a dose indicator.5,6,7,8  
2. Should have accurate and uniform dose delivery  
over a wide range of inspiratory flowrates.9,10  
3. Consistent dose delivery throughout the life of the 
inhaler and consistency of dose when compared to 
other similar inhalers.11 
4. Optimal particle size of drug for deep lung delivery 
.12 
5. Suitability for a wide range of drugs and doses. 
6. Minimum adhesion between drug formulation and 
devices.13  
7. Product stability in the device. 
8. cost-effectiveness.14 
 
First generation DPI devices: 
First generation DPI devices are single unit dose devices 
which are breath activated. The dose delivery is 
dependent on particle size and deagglomeration of drug -
carrier agglomerates or drug carrier mixtures delivered 
by patient inspiratory flow. 
 
 
ABSTRACT: 
Administration of dry powder inhalers (DPIs) for to the management of respiratory diseases has improved significantly in 
modern lifetime. Currently there is a vast margin of available DPIs that differ not only in the design-plan, effective operational 
techniques that are requisite, output features and the delivery of drug across an assortment of inhalation pattern. Diverse 
patient population possibly make choice of individual types of DPI as it is precisely easier to use when in comparison to the 
other types and preferring the right DPI which shall fulfil a particular requirement for patient will certainly enhance the patient 
compliance along with the therapy. For instance some DPIs are found to put forth a greater resistance against inspirational 
flow rate contrast to others which undoubtedly affects the total emitted dose (TED) and also the fine particle fraction (FPF) of 
aerosol that has been released. As a consequence an individual patient may receive different doses of drug while inhaling from 
the different DPIs. For that reason, it is essential that the prescriber should be in complete knowledge of the characteristics of 
different types of DPI, in order to prescribe the device which is most appropriate to the individual patient’s needs. The present 
study sights the features of currently accessible DPIs, evaluates their effectiveness, usage, patient acceptability, drugs 
administered by that inhaler. The variation in output characteristics, availability and patient’s selection between the available 
devices has revealed to have an effect on treatment efficacy and patient compliance through therapy. Altering the DPI that has 
been prescribed to the patient to a cost effective or a generic device may consequently affect disease control and thereby 
amplify the cost of treatment. 
Keywords: Dry powder inhaler; Total emitted dose; DPI design; Resistance; Patient acceptability; Fine particle fraction. 
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Spinhaler: 
Spinhaler is a single dose dry powder inhaler device 
produced by Aventis. Spinhaler, launched by Fisons in 
the late 1967.15 It is similar to that of rotahaler which can 
allow one capsule at one time. The Spinhaler device has 
been used regularly each day by many asthmatics 
without mishap16. It consists of plastic rotar (propeller), 
piercing needles, and mouth piece shown in the fig.117. 
The spinhaler should be  holded in upright position with 
the mouth piece pointing downwards, the body should be 
unscrewed from the  mouth piece then the capsule should 
be placed firmly into the cup of the propeller and fix it 
back to the mouth piece. The capsule can be pierced by 
sliding the outer sleeve. 
Advantages: 
1. Spinhaler is a very safe device 
2. The Spinhaler minimised the need for accurate 
coordination by the patient, while also giving 
manufacturers the opportunity to formulate powders, 
which had important advantages regarding shelf-life 
stability. 
 
Disadvantages: 
1. As it is a single dose device it is loaded each time 
before use. 
2. Spinhaler formulations have difficulty of 
administration and intolerance of use in some 
patients. 
Drugs administered by using spinhaler : 
Salbutamol sulphate, Baclomethasone dipropionate, 
Salbutamol + Baclomethasone dipropionate are the drug 
administered through spinhaler. 
Studies conducted on spinhaler: 
Spinhaler showed lowest fine particle fraction (10%) 
than diskhaler (23%) and turbuhaler (35-40%) at 50-60 
l/min.
 
 
Figure 1: The spinhaler. A) Pictorial Representation B) Schematic Diagram 
 
Rotahaler: 
Rotahaler is a single dose dry powder inhaler device 
produced by GlaxoSmithKline. The capsule filled with 
inhalation must be placed or pushed  into the square hole 
until the  level of the capsule matches to that of the top of 
the square hole by holding the rotahaler vertically. Now 
the rotahaler is holded vertically and the barrel must be 
twisted sharply backward and forward which makes the 
capsule to separate into two parts (cap and body) and 
inhaled through the mouth piece adapter18. 
Advantages: 
1. It has small convenient size and can be used by most 
of the patients. 
2. No need of breath coordination 
Disadvantages: 
1. Every time each dose must be loaded 
2. Difficult for those with restricted finger or hand 
movement to load the rotahaler. 
3. Not suitable for all ages because of its high 
inspiratory flow rates requirement. 
4. Capsules may sometime affected by humidity. 
Drugs Administered By Using Rotahaler: 
 
Table 1: DPI administered through rotahaer 
Drug Strength Brand 
Baclomethasone dipropionate 200mcg, 400 mcg Becotide rotahaler 
Salbutamol 200 mcg Ventolin rotahaler 
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Figure 2: The Rotahaler A) Pictorial Representation B) Schematic Diagram 
 
Cyclohaler: 
cyclohaler is a single dose dpi device produced by  
Pharmachemie. The caps of the cyclohaler was separated 
and turn the mouth piece adapter by holding the device at 
the base and the capsule is placed in the compartment of 
the inhaler and the mouth piece was brought back to the 
closed position. The capsule was pierced by squeezing 
the two blue buttons inward on the base of the inhaler 
and the inhalation was inhaled through the mouth 
piece19. 
Advantages: 
With low intrensic resistance it releases 70 % of the 
metered dose at an inspiratory flow of 28 l/min. 
Drugs administered by using cyclohaler: 
Table 2 indicates the formulation which are administer 
through cyclohaler 
 
Table 2: DPI administered through cyclohaler 
Drug Strength Brand 
Budesonide 200,400 mcg Miflonide® 
Formoterol 12 mcg Foradil® 
Beclomethasone 50,100,250 mcg/100,200,400mcg Becotide®, Miflasone® 
Salbutamol      ------- Sultanol® 
 
 
Figure 3: The cyclohaler A) Pictorial Representation B) Schematic Diagram 
 
Twin Caps
20
 
It is a Single dose dpi device produced by Hovione. 
TwinCaps®, a two-component inhaler with a single step 
to inhalation, approved in October 2010 for marketing in 
Japan with Daiichi Sankyo´s Inavir® influenza anti-viral 
product. Two dose compartments are filled directly with 
drug powder and immediately closed by inserting them 
into the inhaler body. In use, the patient pushes the dose 
compartment sideways and aligns the first dose 
compartment with the mouthpiece. With the inhaler 
ready for use, inhalation can take place. For the second 
dose, the patient pushes the dose compartment in the 
other direction and inhales again. 
Advantages: 
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 Pre-Filled, disposable, low-cost device is needed, with 
extreme ease of use21.  
Studies conducted on twin caps: 
1. In in-vitro tests, the minimum flow rate at which 
TwinCaps® has been shown to deliver 95% of the 
nominal dose is 20 litres per minute 
2. TwinCaps® uses a patented dispersion mechanism in 
which the dose compartment becomes a highly 
turbulent chamber, maximizing fine particle 
fractions. FPFs ranging from 25% to 70% have been 
obtained, at flow rates of 35 litres per minute 
(pressure drop 4kpa). 
Applications: 
TwinCaps has been approved in Japan for the delivery of 
a long-acting neuraminidase inhibitor for the cure and 
prevention of influenza.  
Drugs Administered By Using Twin Caps: 
Anti-virals and antibiotics for lung infection, 
Oncological drugs, pulmonary hypertension drugs are 
administered through twin caps.  
 
 
Figure 4: Twin caps A) closed position B) open position 
 
Flow Caps: 
22
 
Flow caps, a single unit dose DPI device produces by 
havione. FlowCaps® is a capsule-based, re-fillable, 
passive dry-powder inhaler, holding up to 14 capsules. It 
is pen-shaped. It is a simple dry powder inhaler that 
delivers the powder contained in a capsule. The device, 
trademarked FlowCaps® is a manual device without any 
kind of motor or active assistance, thus inhalation occurs 
under the patient’s energy. 
Advantages: 
1. FlowCaps® is one of the most versatile inhalers, 
able to deliver doses in the low-microgram range, to 
multi-milligram (depending on API properties, up to 
10 mg has been successfully delivered). 
2. Emitted dose was found to be 80% and fine particle 
fraction was to be found in the range of 30-70% of 
emitted dose. 
3. Usable at low airflow rates, from as low as 20 litres 
per minute and nominal rate 35 litres per minute. 
4. Inexpensive due to simple, durable construction. 
5. Delivers with high efficiency and low inspiratory 
effort. 
Drugs Administered By Using flow Caps: 
Table 3 indicates the formulation which are administer 
through flowcaps 
Table 3: DPI administered through flowcaps 
Drug Strength Brand 
Salbutamol sulphate 200 mcg Flowcaps 
 
 
Figure 5: Flowcaps A) Pictorial Representation B) Schematic Diagram 
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Aerohaler: 
Aerohaler is a multi-unit dose dpi device produced by 
boehringer-ingeheim.it consists of mouth piece , 
magazine. for operation , the mouthpiece was opened, 
the magazine was slightly turned in clockwise direction 
until the mark is pointing a particular number , to load 
six capsules , the mark should point number six and then 
the magazine was pushed back downwards. the capsules 
are placed into the holes of the magazine and the inhaler 
was closed until the click sound was heared. nad the 
inhalation was  inhaled through the mouth piece. 
 
Advantages: 
A specially designed magazine which tells the number of 
capsules left in the aerohaler. 
Drugs Administered By Using Aerohaler: 
Table 4: DPI administered through aerohaler 
Drug Strength Brand 
Ipratropium bromide 40 mcg Atrovent aerohaler 
 
 
Figure 6: Aerohaler A) Pictorial Representation B) Schematic Diagram 
Novalizer: 
Novalizer is a multiple dose dpi device produced by 
ASTA. Pressing down the red dosage button moves the 
dosing channel backwards releasing powder into the 
dosing chamber. Simultaneously the tapper knocks 
against the cartridge – indicated by a noisy double click, 
so that the powder sinks together and air escapes from 
the dosing chamber avoiding imprecise dosing. At the 
same time the colour in the signal window changes from 
red to green indicating that the inhaler is now ready for 
inhalation. 
 
Drugs Administered By Using Novalizer: 
Table 5 indicates the formulation which are administer 
through novalizer 
Table 5: DPI administered through novalizer 
Drug Strength Brand 
Budesonide 200 mcg Budelin Novalizer 
Budesonide 200,400 mcg Bijsluiter Novalizer 
 
 
Figure7: Novalizer 
Turbuhaler: 
Turbuhaler is multidose Dpi device produced by 
Astrazeneca. Turbuhaler accurately delivers the drug in 
predetermined doses and it is not possible to exceed the 
predetermined dose in any case. The dose indicator gives 
indication to the patient when there are 20 or fewer doses 
remaining indicated by red mark at the bottom of 
Turbuhaler. The drug located within this inhaler is 
formulated as a pellet of a soft aggregate of micronised 
drug which may be formulated with or without any 
additional lactose excipient. The loading of the 
Turbuhaler must be in upright position and later the 
usage can be in any position. The Turbuhaler consists of 
mouthpiece with spiral shaped channels, rotating disk, 
drug reservoir, turning grip, protective cover with 
desiccant. when the grip at the base is fully twisted and 
backed again a single dose is loaded, and the drug get 
filled into holes of the rotating dosing disc, the size and 
number of holes can be changed according to the dose . 
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Under inhalation powder from the holes in dosing disc is 
lifted into inhalation channel into the deaggregation zone 
consists of two spiral channels where the powder get 
deagglomerated under turbulent flow. 
Advantages: 
1. Do not require any shaking before use unlike pMDI's. 
2. All the powder will leave the device with first 200 ml 
of air inhaled. 
3. Easy to use, convenient size and follow the 
instructions by the patient. 
4. No need of breath coordination. 
5. Multidose capacity 
6. Whistle adapter to asses adequate inspiratory flow 
available 
7. Grip attachment for arthritic or restricted finger 
movement to load dose. 
Disadvantages: 
1. No definite guide as to when inhaler is completely 
empty. 
2. Not suitable for all ages. 
3. Unless held upright when the loading the turbohaler, 
the correct dose may not be delivered. 
Patient instructions: 
1. The patient is advised to inhale forcefully and 
deeply 
2. Keep the device upright until loaded 
3. Rinse mouth after use and spit. 
Research activities: 
15-30% of the dose reach the lungs at 60 l/min and 
reduces with decrease in flow rate. 
 Drugs Administered By Using Turbuhaler:  
Table 6 indicates the formulation which are administer 
through turbohaler 
Table 6: DPI administered through turbohaler 
    Drug      Strength  Brand 
Name 
Budesonide 100,200,400 
mcg 
 Pulmicort 
Terbutaline sulphate 500 mcg  Bricanyl 
Eformoterol 
fumarate 
6,12 mcg  Oxis 
Salbutabmol 
sulphate 
50,100 mcg   -- 
 
 
Figure 8: Turbuhaler. A) Pictorial Representation B) Schematic Diagram 
Diskhaler: 
Diskhaler is a multiunit dose dpi device produced by 
glaxosmithkline which was alternative to rotahaler24 . It 
consists of medication disk, hinged lid, a piercing needle, 
and dose indicator. The disk is loaded onto a cartridge 
unit and slided into the outer body and the piercing 
needle, punctures the blister so that the medication is 
inhaled through the mouth piece. The coarse mesh to 
produce turbulence in the stream of air, leading to de-
aggregation. 
Advantages: 
1. Easier to use compared with pMDI's25. 
2. Convenient size and design and easy to use. 
3. No need of breath coordination. 
Disadvantages: 
1. limited doses per disk 
2. May require more than one inspiration per dose. 
3. Not suitable for all ages and require forceful 
inspiration. 
 Patient Instructions:26 
For loading dose inert disk, slide tray, pierce disk and the 
inhalation should be quickly and deeply 
 Drugs Administered By Using Diskhaler: 
Table 7 indicates the formulation which are administer 
through diskhaler 
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Table 7: DPI administered through diskhaler 
Drug  Strength Brand 
Salbutamol 200, 400 mcg Ventodisks 
Baclomethsone Dipropionate 100,200,400 mcg Becodisks 
Salmeterol xinofoate 50 mcg Servent 
Fluticasone propionate 50,100,250 mcg Flixotide. 
 
 
Figure 9: Diskhaler. A) Pictorial Representation B) Schematic Diagram 
Diskus (Accuhaler) 
Diskus is a multi-unit dose dpi device produced by 
glaxosmithkline. It is a plastic device, mainly consists of 
mouthpiece, dose release lever, thumb grip, dose counter, 
the dosage pack is sealed during the manufacture27. The 
external lever helps to load new doses. The rachet-driven 
index wheel guides the foil strip and aligns each newly -
opened blister with air passageways which runs through 
the top of the body into manifold. This enables the 
inhaled air to be drawn through the opened blister, 
aerosolising the contents and delivering the dose through 
the mouthpiece. As each blister is moved into place, the 
lid-foil is peeled away from the base-foil by a contracting 
wheel which collapses progressively as foil collects, thus 
maintaining alignment of the foils within the device. The 
spent base-foil is wound into a separate storage chamber 
designed to retain any residual powder resulting from 
incomplete inhalation. At each completed movement of 
the lever the ratchet can be heard and felt to click into 
place, and an indicator wheel moves on to show the 
number of doses remaining via a small window in the 
body. The disc-shaped device should be used in the 
horizontal plane. The integral outer cover, slid open and 
closed with the help of a thumbgrip, protects the 
mouthpiece and the lever. Once  opened, the Diskus is 
primed by sliding the lever back as far as it will go, until 
a click is heard, followed by inhaling quickly and deeply 
through the mouthpiece. Closing the outer case 
automatically resets the lever. 
Advantages: 
1. Can hold additional doses and easy to use 
2. Two hole mouth piece increase turbulence leading to 
higher deagglomeration . 
3. Dose counter indicating how many doses are left. 
Disadvantages: 
1. Mouthpiece is too shallow. 
2. Dose indicator can be reset which may mislead the 
patient in using the empty inhaler. 
Patient instructions: 
Open, slide and inhalation should be sucked in quickly 
and deeply. 
Studies conducted: 
1. Salbutamol Diskus Showed Low Fine Particle 
Fraction That Is 28,26,19% At Air Flow Rate 90,60 
And 30 Min-1 When Compared With Disk Haler 
Which Showed 47,40 And 25% Of Fine Particle 
Fraction At 90,60and 30 Min-1.28 
2. Diskus showed 93% accuracy and 93% consistency 
which compared to diskhaler which showed 56% 
accuracy and 67% consistency an turbuhaler showed 
32% accuracy and 61% consistency29. 
  Drugs Administered By Using Diskus: 
Table 8 indicates the formulation which are administer 
through diskus 
 
Table 8: DPI administered through diskus 
Drug Strength Brand 
Salbutamol 200 mcg Ventolin 
Salmeterol 50 mcg Servent 
Fluticasone propionate 100,250,500 mcg Flixotide 
Salmeterol + fluticasone propionate 50+100,250,500 mcg Seretide 
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Figure 10: Diskus 
 
Clickhaler: 
Clickhaler is a multi-dose dpi device produced by 
Innoveta biomed, click haler consists of 14 plastic 
components and to two compression springs helps to 
hold cone tightly and seals the base of the reservoir made 
of steel, dosing metering elements which consists of 
metering cone, bulk drug reservoir and compression 
spring. Due to the gravity the metering cup in the cone 
are filled as it rotates, carring the dose of inhalation into 
the passage, where it aerolises aiding the deaggregation. 
The dose indicator indicates at last ten doses with red 
warning. 
Advantages: 
1. One metered dose delivered at once, reoperation of 
device automatically removes an unused dose into a 
waste reservoir. 
2. The children 0f 6 years of age can achieve active 
inspiratory flow rates of sufficient drug delivery to 
lungs30,31,32,33,34. 
Disadvantages: 
Need a rapid and deep inhalation for optimal dose 
delivery. 
Patient Instructions: 
The inhaler should be in upright position, shake and 
press during priming and inhalation should be steady and 
deeply. 
Research Activities: 
A higher proportion of the inhaled dose is delivered into 
the lungs by clikhaler than baclomethasone pMDI and 
budesonide turbuhaler35,36.  
Drugs administered by using clickhaler: 
Table 9 indicates the formulation which are administer 
through clickhaler 
Table 9: DPI administered through clickhaler 
Drug Strength Brand 
Salbutamol ---------------- Asmasal 
Baclomethasone 
dipropionate 
50,100,250 mcg Asmabec 
 
 
Figure 11: Clickhaler A) Pictorial Representation B) 
Schematic Diagram 
Pulvinal: 
Pulvinal is a multiple dose dpi device produced by chiesi 
farmaceutici. Pulvinal is very similar to that of 
Turbuhaler by having a mouth piece and basal turning 
grip and a protective cap which can be unscrewed before 
use. The priming is done by holding the inhaler in 
upright position and tapping on the surface to level the 
powder in metering chamber, then the button on the side 
of the mouth piece was pressed with one hand while 
twisting the body a half turn anticlock wise and back 
again. 
Advantages: 
Indicates the correct dosing positing by click sound and a 
red marker when body was twisted and another click 
sound and the green marker will be indicted when the 
body is twisted back into the correct position37. 
Disadvantages: 
It has high resistance to air flow, which made the healthy 
volunteer unable to reach the flow rate more than 50 
lit/min when study conducted on 10 healthy volunteers, 
during a gamma scintigraphic drug deposition studies 
Drugs Administered By Using pulvinal: 
Table 10 indicates the formulation which are administer 
through pulvinal 
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Table 10: DPI administered through pulvinal 
Drug Strength Brand 
Salbutamol 200 mcg Pulvinal salbutamol 
Baclomethasone dipropionate 100,200 and 400 mcg Pulvinal Baclomethasone 
dipropionate 
 
 
Figure 12: Pulvinal 
 
Easyhaler: 
Easyhaler is a multiple dose reservoir Dpi device 
produced by Orion Parma. The sequence of operation 
and shape is almost similar to that of pMDI. 
It consists of seven plastic components and one metering 
spring. The metering cylinder inside the housing just 
below the reservoir, which contains sufficient powder for 
a minimum of 200 doses. the chamber cover is covered 
by a spring and the overcap, from which two prongs 
engage directly with ratcheted edges of the metering 
cylinder. This enables each drug dose to be delivered by 
pushing down once on the overcap to rotate the metering 
cylinder. The next dose cavity, filled under gravity with 
powder from the reservoir, is thus positioned into the 
mouth piece, through which the drug is inhaled. 
Advantages: 
1. There is no waste of drug, in case of the double 
activation the unused dose is returned back to the 
reservoir. 
2. The dose indicator indicated at the last 20 doses with 
red marker which is connected to ratcheted 
measuring cylinder. 
3. High shielded protective cover is included to reduce  
moisture penetration into inhaler38. 
Disadvantages: 
This device have high resistance so require high 
inspiratory flow rate39. 
Studies Conducted: 
salbutamol easyhaler showed good correlation with that 
of ventolin pMDI40 and deliver dose and respirable 
fraction  was found to be relatively unaffected after 
stability studies41. 
Drugs Administered By Using Easyhaler: 
Table 11: indicates the formulation which are administer 
through easyhaler 
Table 11: DPI administered through easyhaler 
Drug Strength Brand 
Salbutamol 100,200 mcg Buventol, Buventol 
forte. 
Baclomethasone 
dipropionate 
200, 400 mcg Beclomet 
Easyhaler. 
 
 
Figure 15: Easyhaler 
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Third Generation DPI devices: 
These are active devices employs compressed gas or 
mortar driven impellers or use of electronic 
vibration42,43,44. 
Exubera: 
Exubera being an inhalation powder has a white to off-
white coloured powder in a unit dosed blister. Each unit 
dose blister of exubera consists of 1 mg or 3 mg dose of 
insulin in a homogeneous powder that contains sodium 
citrate dihydrate, glycine, mannitol and sodium 
hydroxide. The exubera blister is usually inserted into the 
inhaler where the patient pumps the handle of the inhaler 
by pressing a button that causes the blister to get pierced. 
The insulin inhalation powder is thus by distributed into 
the chamber, letting the patient to breathe in the released 
aerosolized powder. In standardized in vitro test 
conditions, EXUBERA being a metered dose device 
delivers a specific amount of insulin dose from the 
mouthpiece. A small part of the total particle mass as 
fine particles that are capable of reaching the deep lung 
is emitted. There can be a retainment upto 45% in the 1 
mg blister contents, and up to 25% in the 3 mg blister 
contents in the blister. 
Advantages: 
Cost effective when compared to that of insulin injection. 
 
Figure 14: Exubera 
CONCLUSION: 
The main aim of the article is to emphasize on different 
DPI devices available dry powder inhalation delivery. 
Pulmonary drug delivery is a promising route of 
administration, being non-invasive and ensuring patient 
compliance. Till date the production of Inhaler 
economically with the promising performance is yet to 
be accomplished. The applications of DPI provide an 
opportunity to augment the efficiency for aged patients. 
According to the food and drug administration (FDA) it 
is recommended to add a necessary part like an integral 
dose counter as an active part of DPI device. With the 
advancing technology, the future DPI devices may add 
other features like dose reminder, audiovisual signals of 
dose delivery, measurement of flow rates during 
inhalation. In addition to device design great concern is 
between interaction between the formulation device, the 
factors which needs to be given due importance before 
designing a new device. The consequence of DPI 
formulation (type of lactose and physicochemical 
properties of drug), capsule material and inhalers on the 
charge and polarity of DPI aerosols are dependent on the 
type of inhaler, carrier size, and capsule size that are 
considered and used in the experimentation process. 
Before formulating the factors which influence the 
formulations must be considered for an ideal inhaler 
which would result in the product which tend them to be 
reliable, efficient, user and eco-friendly, and cost 
effective. Drug delivery mechanism is essential to 
rationalise design of Devices with promising 
performance. In days to come the drugs synthesized 
biotechnologically require the aid of devices which can 
deliver the drug efficiently targeting the lower airway of 
lungs. There is a great demand for the innovative DPI's 
for the treatment of the conditions of like diabetes, 
cancer, CNS disorders and cystic fibrosis. The recent 
focus of regulatory requirements mandates that there 
should be a minimum dependence on the inspiration flow 
rates of an individual as well as reproducible aerosol 
performance to attain optimum compliance and activity. 
The farther development of DPI Products should focus 
on both inhaler device powder formulation for desired 
therapeutic benefits over risks.This may also lead to 
development of a device which is disposable in nature 
the emancipates the regular cleaning of device time to 
time, eliminating the concerns for the stability thereby 
rendering it less expensive and higher patient compliance 
and safety. Therefore  to explore the full potential of 
DPI's which are of less expenditure and budget to 
Pharmaceutical Giants and patients innovation of a 
Novel device with augmented lung targeting, disposition 
and reliability on device would form a key area in days 
to come and explore.  
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